Reuters Health adds new executive editor

Share this article:
Reuters Health adds new executive editor
Reuters Health adds new executive editor
Reuters Health hired Ivan Oransky as executive editor, heading editorial operations for the company's global medical and healthcare news services. The appointment is effective June 15.

“Joining Reuters Health is a great opportunity to lead a talented team that has built a highly authoritative, comprehensive and successful news service over the years,” Oransky told the Association of Health Care Journalists (AHCJ). Oransky was elected to the AHCJ's board in 2002.

Vincent Baby, VP of news services for Reuters News Agency, said in a statement that Oransky's academic and professional track record “make him the ideal person to develop Reuters Health and further leverage the unique assets of Thomson Reuters in the scientific and healthcare arena for the benefit of our professional and media customers.”

Oransky was previously an online managing editor at Scientific American, where he oversaw “significant content expansion and high traffic growth,” according to a statement. In addition to AHCJ, Oransky is also a member of the National Association of Science Writers.

The move follows the planned retirement of Robert Saunders, who has been at the editorial helm of Reuters Health for over a decade.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...